• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·US·Healthcare·NWCI
Share

NewCardio, Inc. Stocks

$ 0Last Updated 23.10.2026

Issuer Rating

Performance

Strong

Risk

High

Recommendation

Sell

Market Cap

$ 3315

$ 0
Key Takeaways

Risk factor

Very high price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Greatly undervalued vs peers

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

NewCardio, Inc. is a company dedicated to cardiac diagnostics and related services. Its primary objective is the research, creation, and market introduction of exclusive software platform technologies. These innovations are designed for two main applications: the non-invasive diagnosis and continuous monitoring of cardiovascular diseases (CVD), and the assessment of cardiac safety for experimental drugs. The company's underlying technology analyzes the heart's electrical activity in real-time and in three dimensions, using data gathered from the body's surface via standard 12-lead electrocardiogram (ECG) electrodes. NewCardio is also actively developing several products. QTinno, for instance, is an automated solution for cardiac safety, utilizing algorithms to automatically measure, analyze, and report on collected ECGs, thereby streamlining traditional manual or semi-automated methods. Another product, CardioBip, is a mobile ECG system for remote transmission, comprising a portable recording and transmitting device along with web-based software that receives, processes, and interprets the data. Furthermore, the company is progressing with my3KG, a software application intended to provide a comprehensive method for evaluating cardiac electrical activity across both time and space. NewCardio, Inc. was founded in 2004 and is headquartered in Branchburg, New Jersey.

Company Valuation

Greatly undervalued
7/7

From both historical and forecast perspectives, the stock is considerably underpriced compared to similar stocks.

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

24.10.2026 16:01

Highlights in Small-Cap Stocks: The Merck Deal, the Success of a Hair Loss Pill, and Braze's "Wow Factor"

24.10.2026 13:01

AI investors are already on the brink, a “French kiss” for the euro, and hackers at the gates

24.10.2026 05:04

Hedge funds have ramped up their bets against the euro to a 2020 high

24.10.2026 04:46

France Avoided a Downgrade by Moody’s After a Week of Crisis

24.10.2026 04:37

A key Novartis drug failed to meet expectations. The stock price fell

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026